Literature DB >> 9390561

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.

T Imai1, K Hieshima, C Haskell, M Baba, M Nagira, M Nishimura, M Kakizaki, S Takagi, H Nomiyama, T J Schall, O Yoshie.   

Abstract

Leukocyte trafficking at the endothelium requires both cellular adhesion molecules and chemotactic factors. Fractalkine, a novel transmembrane molecule with a CX3C-motif chemokine domain atop a mucin stalk, induces both adhesion and migration of leukocytes. Here we identify a seven-transmembrane high-affinity receptor for fractalkine and show that it mediates both the adhesive and migratory functions of fractalkine. The receptor, now termed CX3CR1, requires pertussis toxin-sensitive G protein signaling to induce migration but not to support adhesion, which also occurs without other adhesion molecules but requires the architecture of a chemokine domain atop the mucin stalk. Natural killer cells predominantly express CX3CR1 and respond to fractalkine in both migration and adhesion. Thus, fractalkine and CX3CR1 represent new types of leukocyte trafficking regulators, performing both adhesive and chemotactic functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390561     DOI: 10.1016/s0092-8674(00)80438-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  420 in total

Review 1.  Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system.

Authors:  O Yoshie
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Role of chemokines in inflammation and immunoregulation.

Authors:  L Feng
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 4.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

6.  Decreased Th17 and antigen-specific humoral responses in CX₃ CR1-deficient mice in the collagen-induced arthritis model.

Authors:  Teresa K Tarrant; Peng Liu; Rishi R Rampersad; Denise Esserman; Lisa R Rothlein; Roman G Timoshchenko; Marcus W McGinnis; David J Fitzhugh; Dhavalkumar D Patel; Alan M Fong
Journal:  Arthritis Rheum       Date:  2012-05

7.  Application of an electrochemiluminescence assay for quantification of E6011, an antifractalkine monoclonal antibody, to pharmacokinetic studies in monkeys and humans.

Authors:  Muneo Aoyama; Yuji Mano
Journal:  J Clin Lab Anal       Date:  2018-07-20       Impact factor: 2.352

8.  Regulation of CX3CL1 Expression in Human First-Trimester Decidual Cells: Implications for Preeclampsia.

Authors:  S Joseph Huang; Chie-Pein Chen; Lynn Buchwalder; Ya-Chun Yu; Longzhu Piao; Chun-Yen Huang; Frederick Schatz; Charles J Lockwood
Journal:  Reprod Sci       Date:  2019-01-03       Impact factor: 3.060

9.  Cloning and functional characterization of the human fractalkine receptor promoter regions.

Authors:  Alexandre Garin; Philippe Pellet; Philippe Deterre; Patrice Debré; Christophe Combadière
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

10.  Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.

Authors:  Yung-Ming Chen; Chao-Jung Tu; Kung-Yu Hung; Kwan-Dun Wu; Tun-Jun Tsai; Bor-Shen Hsieh
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.